MARTINGALE RESEARCH CORPORATION — Department of Health and Human Services SBIR Phase I: 400

MARTINGALE RESEARCH CORPORATION — SBIR Phase I award from Department of Health and Human Services.

Amount
$224,995
Agency
Department of Health and Human Services · National Institutes of Health
Program / Phase
SBIR · Phase I
Topic
400
Solicitation
PA14-071
NAICS
Place of performance
TX
Period
2015-09-01 → 2016-08-31

Description

DESCRIPTION provided by applicant Chronic critical illness CCI leads to extended stays in intensive care units reduces quality of life adds nearly $ billion annually in health relate costs and is a precursor to other conditions such as persistent inflammation immunosuppression and catabolism syndrome PICS At any one time more than patients suffer from CCI in the United States alone CCI for surgical trauma patients is defined as an intensive care unit stay greater than or equal to days with evidence of ongoing organ dysfunction The availability of existing clinical data characterizing CCI provides the opportunity to apply advanced statistical methods to develop robust patient level CCI risk models for trauma and sepsis research More effective risk models are invaluable to practitioners administrators and policy makers and lead to better decisions resulting in increased patient quality of life and reduced health care costs Despite widespread use of patient level prediction models for clinical events e g mortality to compute severity of illness scores patient level CCI risk models are not currently available Moreover recent advances in statistics that can be applied to robust risk modeling of underlying pathologies are not easily accessible to health care researchers Thus utilizing improved statistical methods for developing a CCI risk model that can reveal the etiology for the disease not merely predict onset would significantly help scientists understand assess prevent and treat CCI This Phase I study investigates the feasibility of applying a Best Approximating Model BAM method to develop improved risk models for CCI on a NIGMS sponsored dataset for a population of severely injured blunt trauma patients The BAM method is a systematic model development approach that combines robust estimation specification analyses stochastic exhaustive model search and model validation within the single model selection validation framework of a generalized additive model A BAM is designed to handle common problems encountered in developing predictive risk models including possible model misspecification missing values and overfitting as well as multicollinearity small sample size bias and Type I error inflation due to multiple model comparisons In this Phase I study a robust CCI risk model will be developed using an in house BAM method followed by a series of simulation studies designed to evaluate its performance The simulation studies will also characterize the advantages of the BAM strategy for developing a robust CCI risk model over conventional statistical methods such as stepwise regression Feasibility study results will provide the preliminary research needed for more advanced Phase II CCI risk model development evaluation and dissemination that in turn will establish the essential foundation for Phase III commercialization of an advanced prognostic technology PUBLIC HEALTH RELEVANCE Chronic critical illness CCI leads to extended stays in intensive care units reduces quality of life adds nearly $ billion annually in health related costs and is a precursor to other conditions such as persistent inflammation immunosuppression and catabolism syndrome PICS At any one time more than patients suffer from CCI in the United States alone Detecting its clinical predictors following traumatic injury would provide the opportunity to test clinical interventions designed to prevent CCI following surgery Utilizing recent advances in robust statistical modeling this Phase I study will develop and evaluate the performance of a practical CCI risk model on a NIGMS sponsored dataset disseminate findings to scientists studying CCI and PICS establish feasibility for more advanced Phase II CCI risk model development validation evaluation and dissemination and provide the foundation for Phase III commercialization of an advanced prognostic technology